Real-world fusion landscape in advanced Chinese pancreatic cancer using next generation sequecing: A multicenter study

Date 23 November 2019
Event ESMO Asia Congress 2019
Session Poster display session
Topics Personalised/Precision Medicine
Pancreatic Cancer
Presenter Yiyu Shen
Citation Annals of Oncology (2019) 30 (suppl_9): ix122-ix130. 10.1093/annonc/mdz431
Authors Y. Shen1, S. Fang2, X. Cai3, Y. Fang4, R. Lin5, Y. Zhang6, J. Li7, X. Liang8, L. Wang9, L. Lin10, L. Zhang11, H. Feng12, S. Lan13, X. Cai14, C. Xu15, W. Wang16, M. Fang16, J. Zhang17
  • 1Hepatobiliary Surgery, The Second Affiliated Hospital of Jiaxing Medical College, 314000 - Jiaxing/CN
  • 2Pathology, Daping Hospital and Research Institute of Surgery, Army Medical University, 400042 - Chongqing/CN
  • 3Oncology, Sun Yat-sen University Cancer Hospital, 510060 - Guangzhou/CN
  • 4Oncology, Sir Run Run Shaw Hospital, Zhejiang University, 310016 - Hangzhou/CN
  • 5Oncology, Fujian Cancer Hospital, 3500014 - Fuzhou/CN
  • 6Oncology, The Second Affiliated Hospital of Medical College, Xi’an Jiaotong University, 710004 - Xi’an/CN
  • 7Radiotherapy, Xiamen Cancer Hospital, 361003 - Xiamen/CN
  • 8Oncology, The Third People’s Hospital of Zhengzhou, 450000 - Zhengzhou/CN
  • 9Oncology, Baotou Cancer Hospital, 014030 - Baotou/CN
  • 10Oncology, Peking University International Hospital, 102206 - Beijing/CN
  • 11Pathology, Daxing Teaching Hospital of Capital Medical University, 102600 - Beijing/CN
  • 12Oncology, Shanxi Dayi Hospital, Shanxi Academy of Medical Science, 030032 - Taiyuan/CN
  • 13Oncology, The First Hospital of Jilin University, 130021 - Changchun/CN
  • 14Oncology, the First Affiliated Hospital of Dalian Medical University, 116011 - Dalian/CN
  • 15Pathology, Fujian Cancer Hospital, 350014 - Fuzhou/CN
  • 16Chemotherapy, Zhejiang Cancer Hospital, 310022 - Hangzhou/CN
  • 17Oncology, The Seven Medical Centre of Chinese PLA General Hospital, 100071 - Beijing/CN

Abstract

Background

The therapeutic targets of pancreatic cancer (PC) are fewer. Cell-free DNA (cfDNA) has been a research hotspot in molecular tumour profiling. In advanced PC patients, malignant abdominal dropsy provides a wealth of tumour cells that can be investigated. The aim of this study is to investigate fusion landscape in advanced PC.

Methods

A multicenter study in China was initiated from Oct. 2016, and PC patients have been enrolled as of Apr. 2019. To determine the fusion frequency in PC, we analysed data from 536 clinical PC cases, each of which had results from next-generation sequencing (NGS)-based 808 genes panel assay, analogous to the index patient.

Results

Of this entire cohort, 24 patients (4.48%) were identified with fusions, including ARID1A-PIGV (1), HSD3BP4-HSD3B1 (1), CDKN2A-MTAP (1), PDE10A-BRAF (1), ETV6-NTRK3 (1), NOTCH1-RABL6 (1), ERRFI1-SLC25A33 (1),BRCA1-PTGES3L (1),MYCN-LINC00299 (1), CREBBP-CDIP1 (1), LPAR5-CHD4 (1), PMS2-ETV1 (1), RPTOR-ASPSCR1 (1), CHD2-SLCO3A1 (1), IDH2-SEMA4B (1), BAIAP2-RPTOR (1), CHEK1-OSBP (1), LRP1-KRT81 (1), TBX3-ACSS3 (1), RAB11FIP1-GPR124 (1), AXIN1-SNX29 (1), PPP2R1A-ZNF415 (1), BCL2L14-ETV6 (1) and BMX-NHS (1). BRAF, NTRK and BRCA1 fusions were seen in 12.50% (3/24) advanced Chinese pancreatic cancer fusion landscape patients. These three patients were diagnosed with pancreatic duct adenocarcinoma. For treatments, the BRAF fusion patient chose vemurafenib, another two patients chose chemotherapy, and this case of BRAF fusion patient responding to vemurafenib was actively being sought thru our database.

Conclusions

Advanced Chinese pancreatic cancer fusion landscape is rich, BRAF and NTRK fusions are rare but potentially druggable in TKIs. Detection of BRAF, NTRK, BRCA1, EGFR, ALK, ROS1, RET and ERBB2 fusions should be part of comprehensive profiling panels to determine TKIs and direct appropriate combination therapeutic strategies.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Yiyu Shen.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.